Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice

Journal of Medicinal Chemistry

Volumn 50, Issue 9, 2007, Pages 2264-2268

  Lumb, Kevin J ^a   DeCarr, Lynn B ^a   Milardo, Lucinda F ^a   Mays, Michelle R ^a   Buckholz, Thomas M ^a   Fisk, Stephen E ^a   Pellegrino, Carla M ^a   Ortiz, Astrid A ^a   Mahle, Cathy D ^a  

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL; NEUROPEPTIDE Y RECEPTOR AGONIST; NEUROPEPTIDE Y2 RECEPTOR; PEPTIDE YY; PEPTIDE YY [25-36]; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; FOOD INTAKE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OBESITY; PEPTIDE SYNTHESIS; WEIGHT REDUCTION;

ANIMALS; ANTI-OBESITY AGENTS; BODY WEIGHT; CYCLIC AMP; EATING; HUMANS; MALE; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; PEPTIDE YY; POLYETHYLENE GLYCOLS; RADIOLIGAND ASSAY; RECEPTORS, NEUROPEPTIDE Y; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247598752     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061454v     Document Type: Article

References (21)

1. 3-36 in the treatment of obesity. Expert Opin. Invest. Drugs 2005, 14, 647-53.
2. 3-36 physiologically inhibits food intake. Nature 2002, 418, 650-654.
3. 3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem. Biophys. Res. Commun. 2003, 311, 915-919.
4. 3-36 inhibits food intake in mice through a melancortin-4 receptor-independent mechanism. Endocrinology 2004, 145, 2585-2590.
5. Pittner, R. A.; Moore, C. X.; Bhavsar, S. P.; Gedulin, B. R.; Smith, P. A.; Jodka, C. M.; Parkes, D. G.; Paterniti, J. R.; Srivastava, V. P.; Young, A. A. Effects of PYY[3-36] in rodent models of diabetes and obesity. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 963-971.
6. 7-36 inhibit food intake additively. Endocrinology 2005, 146, 5120-5127.
7. Adams, S. H.; Lei, C.; Jodka, C. M.; Nikoulina, S. E.; Hoyt, J. A.; Gedulin, B.; Mack, C. M.; Kendall, E. S. PYY[3-36] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice. J. Nutr. 2006, 136, 195-201.
8. Vrang, N.; Madsen, A. N.; Tang-Christensen, M.; Hansen, G.; Larsen, P. J. PYY(3-36) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity. Am. J. Physiol.: Regul., Integr. Comp. Physiol. 2006, 291, R367-75.
9. 3-36. N. Engl. J. Med. 2003, 349, 941-948.
10. Cox, J. E.; Randich, A. Enhancement of feeding suppression by PYY(3-36) in rats with area postrema ablations. Peptides 2004, 25, 985-989.
11. Abbott, C. R.; Small, C. J.; Kennedy, A. R.; Neary, N. M.; Sajedi, A.; Ghatei, M. A.; Bloom, S. R. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res. 2005, 1043, 139-144.
12. 3-36 potently inhibits food intake in rats. Endocrinology 2005, 146, 879-888.
13. 3-36 on food intake in humans. Gastroenterology 2005, 129, 1430-1436.
14. Koegler, F. H.; Enriori, P. J.; Billes, S. K.; Takahashi, D. L.; Martin, M. S.; Clark, R. L.; Evans, A. E.; Grove, K. L.; Cameron, J. L.; Cowley, M. A. Peptide YY(3-36) inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 2005, 54, 3198-3204.
15. Moran, T. H.; Smedh, U.; Kinzig, K. P.; Scott, K. A.; Knipp, S.; Ladenheim, E. E. Peptide YY(3-36) inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am. J. Physiol.: Regul., Integr. Comp. Physiol. 2005, 288, R384-R388.
16. 3-36) in rabbits. Int. J. Obes. 2006, 30, 68-72.
17. Hu, Y.; Bloomquist, B. T.; Cornfield, L. J.; DeCarr, L. B.; Flores-Riveros, J. R.; Friedman, L.; Jiang, P.; Lewis-Higgins, L.; Sadlowski, Y.; Schaefer, J.; Velazquez, N.; McCaleb, M. L. Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior. J. Biol. Chem. 1996, 271, 26315-26319.
18. 1 receptor agonists with orexigenic activity in vivo. Mol. Pharmacol. 2001, 60, 534-540.
19. DeCarr, L. B.; Buckholz, T. M.; Coish, P. D.; Fathi, Z.; Fisk, S. E.; Mays, M. R.; O'Connor S, J.; Lumb, K. J. Identification of selective neuropeptide Y2 peptide agonists. Bioorg. Med. Chem. Lett. 2007, 17, 538-541.
20. Harris, J. M.; Chess, R. B. Effect of PEGylation on pharmaceuticals. Nat. Rev. Drug Discovery 2003, 2, 214-221.
21. Ravinet Trillou, C.; Arnone, M.; Delgorge, C.; Gonalons, N.; Keane, P.; Maffrand, J. P.; Soubrie, P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol.: Regul., Integr. Comp. Physiol. 2003, 284, R345-R353.